- Reported transaction lines
- 5
- Buy lines
- 0
- Sell lines
- 4
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-115
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Hallen Ed Director · 10% owner · Klaviyo, Inc. | KVYO Klaviyo, Inc. | Gift or transferFiling detailsSEC transaction code G Series A Common Stock · Indirect ownership · By Hodgkins LLC · Reported balance after transaction: 292746 · Represents a bona fide gift of 17,885 shares of stock from Hodgkins LLC, of which Reporting Person serves as manager, to a donor-advised fund pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. · Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. | 2026-11-05 | 2026-11-09 | 17,885 shares/units | SEC 4 |
| Hallen Ed Director · 10% owner · Klaviyo, Inc. | KVYO Klaviyo, Inc. | SellFiling detailsSEC transaction code S Series A Common Stock · Indirect ownership · By Hodgkins LLC · Reported balance after transaction: 310631 · SEC code covers open-market or private transactions · These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. · The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.97 to $21.14 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. | 2026-11-05 | 2026-11-09 | ≈ $296,180.99 14,057 shares/units | SEC 4 |
| Hallen Ed Director · 10% owner · Klaviyo, Inc. | KVYO Klaviyo, Inc. | SellFiling detailsSEC transaction code S Series A Common Stock · Indirect ownership · By Hodgkins LLC · Reported balance after transaction: 324688 · SEC code covers open-market or private transactions · These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. · The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.15 to $22.14 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · Shares held by Hodgkins LLC, of which the Reporting Person serves as manager. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. | 2026-11-05 | 2026-11-09 | ≈ $980,408.16 45,558 shares/units | SEC 4 |
| Hallen Ed Director · 10% owner · Klaviyo, Inc. | KVYO Klaviyo, Inc. | SellFiling detailsSEC transaction code S Series A Common Stock · Indirect ownership · By Hodgkins Trust · Reported balance after transaction: 16123 · SEC code covers open-market or private transactions · These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. · The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.62 to $20.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. | 2026-11-05 | 2026-11-09 | ≈ $134,697.84 6,504 shares/units | SEC 4 |
| Hallen Ed Director · 10% owner · Klaviyo, Inc. | KVYO Klaviyo, Inc. | SellFiling detailsSEC transaction code S Series A Common Stock · Indirect ownership · By Hodgkins Trust · Reported balance after transaction: 22627 · SEC code covers open-market or private transactions · These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 1, 2026. · The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.99 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · Shares are owned directly by Hodgkins Trust for the benefit of the Reporting Person and the Reporting Person's family, and of which the trustee is an independent institution. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. | 2026-11-05 | 2026-11-09 | ≈ $697,355.05 32,663 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.